Immunomodulation therapy for invasive aspergillosis: Discussion on myeloid growth factors, recombinant cytokines, and antifungal drug immune modulation

Current Fungal Infection Reports

Volumn 4, Issue 1, 2010, Pages 1-7

  Safdar, Amar ^a  

^a NONE

Author keywords

Antifungal immune modulation; Cancer; Fungal infections; Fungal pathogenesis; G CSF; GM CSF; Immunotherapy; Interferon gamma; Invasive aspergillosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA GLUCAN; CORTICOSTEROID; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ECHINOCANDIN; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; POSACONAZOLE; RECOMBINANT GAMMA INTERFERON; SCAVENGER; TRIAZOLE;

ADD ON THERAPY; ANTIBODY PRODUCTION; ANTIFUNGAL ACTIVITY; BONE MARROW SUPPRESSION; CELL WALL; CHRONIC GRANULOMATOUS DISEASE; CYTOKINE RELEASE; ENZYME RELEASE; FUNGAL VIRULENCE; FUNGUS HYPHAE; FUNGUS SPORE; GRAFT VERSUS HOST REACTION; GRANULOCYTE TRANSFUSION; HELPER CELL; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOTHERAPY; INVASIVE ASPERGILLOSIS; LUNG ALVEOLUS MACROPHAGE; MYCOSIS; NATURAL KILLER CELL; NEUTROPENIA; NONHUMAN; PATHOGENESIS; POPULATION; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT FAILURE;

EID: 77449144181     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0006-x     Document Type: Review

References (62)

1. Neofytos D, Horn D, Anaissie E, et al.: Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
2. Chamilos G, Luna M, Lewis RE, et al.: Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91:986-989.
3. Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653. (Pubitemid 41170352)
4. Leventakos K, Lewis RE, Kontoyiannis DP: Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010, 50:405-415.
5. Gerson SL, Talbot GH, Hurwitz S, et al.: Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984, 100:345-351. (Pubitemid 14156535)
6. Yuen KY, Woo PC, Ip MS, et al.: Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997, 25:37-42. (Pubitemid 27293073)
7. Marr KA, Carter RA, Boeckh M, et al.: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366. (Pubitemid 35429674)
8. Paczesny S, Hanauer D, Sun Y, Reddy P: New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2010, 45:1-11.
9. Safdar A, Rodriguez GH, De Lima MJ, et al.: Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 2007, 86:324-333.
10. Safdar A, Rodriguez GH, Mihu CN, et al.: Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2009 Jun 29 (Epub ahead of print).
11. Safdar A: Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006, 38:327-337.
12. Brown GD, Gordon S: Immune recognition of fungal betaglucans. Cell Microbiol 2005, 7:471-479.
13. Wheeler RT, Fink GR: A drug-sensitive genetic network masks fungi from the immune system. PloS Pathol 2006, 2:e35. In this article, Wheeler and Fink have shown the impact of immunologically active fungal antigen exposure following fungal cell wall-active drugs and the ancillary immune modulatory role of fungicidal drugs.
14. Mircescu MM, Lipuma L, van Rooijen N, et al.: Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J Infect Dis 2009, 200:647-656.
15. Park SJ, Hughes MA, Burdick M, et al.: Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis. J Immunol 2009, 182:4306-4312.
16. Gafa V, Lande R, Gagliardi MC, et al.: Human dendritic cells following Aspergillus fumigatus infection express the CCR7 receptor and a differential pattern of interleukin-12 (IL-12), IL-23, and IL-27 cytokines, which lead to a Th1 response. Infect Immun 2006, 74:1480-1489. (Pubitemid 43346780)
17. Zelante T, De Luca A, Bonifazi P, et al.: IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007, 37:2695-2706. (Pubitemid 47578289)
18. Zelante T, De Luca A, D'Angelo C, et al.: IL-17/Th17 in antifungal immunity: what's new? Eur J Immunol 2009, 39:645-648.
19. Armstrong-James DP, Turnbull SA, Teo I, et al.: Impaired interferon-gamma responses, increased interleukin-17 expression, and a tumor necrosis factor-alpha transcriptional program in invasive aspergillosis. J Infect Dis 2009, 200:1341-1351.
20. Bergmann A, Hartmann T, Cairns T, et al.: A regulator of Aspergillus fumigatus extracellular proteolytic activity is dispensable for virulence. Infect Immun 2009, 77:4041-4050.
21. Alp S, Arikan S: Investigation of extracellular elastase, acid proteinase and phospholipase activities as putative virulence factors in clinical isolates of Aspergillus species. J Basic Microbiol 2008, 48:331-337.
22. Ben-Ami R, Lewis RE, Leventakos K, et al.: Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 2009, 114:5393-5399.
23. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415. (Pubitemid 34851833)
24. Rowe JM: Concurrent use of growth factors and chemotherapy in acute leukemia. Curr Opin Hematol 2000, 7:197-202.
25. Smith TJ, Khatcheressian J, Lyman GH, et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205. (Pubitemid 46638957)
26. Godwin JE, Kopecky KJ, Head DR, et al.: A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998, 91:3607-3615.
27. Heil G, Hoelzer D, Sanz MA, et al.: A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997, 90:4710-4718. (Pubitemid 28007183)
28. Smith TJ, Khatcheressian J, Lyman GH, et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205. (Pubitemid 46638957)
29. Lyman GH, Kleiner JM: Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw 2007, 5:217-228. (Pubitemid 46423060)
30. Roilides E, Uhlig K, Venzon D, et al.: Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993, 61:1185-1193. (Pubitemid 23099183)
31. Polak-Wyss A: Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 1991, 34:205-215.
32. Roilides E, Uhlig K, Venzon D, et al.: Prevention of corticosteroid- induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993, 61:4870-4877. (Pubitemid 23320547)
33. Sionov E, Mendlovic S, Segal E: Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005, 56:594-597. (Pubitemid 41264143)
34. Graybill JR, Bocanegra R, Najvar LK, et al.: Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998, 42:2467-2473. (Pubitemid 28462881)
35. Patera AC, Menzel F, Jackson C, et al.: Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob Agents Chemother 2004, 48:3154-3158. (Pubitemid 38989192)
36. Dornbusch HJ, Urban CE, Pinter H, et al.: Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatr Hematol Oncol 1995, 12:577-586.
37. Brummer E, Kamberi M, Stevens DA: Regulation by granulocytemacrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis 2003, 187:705-709. (Pubitemid 36250039)
38. Choi JH, Brummer E, Kang YJ, et al.: IkB and NFkB in GM-CSF antagonism of dexamethasone suppression of macrophage response to Aspergillus fumigatus conidia. J Infect Dis 2006, 193:1023-1028.
39. Roilides E, Blake C, Holmes A, et al.: Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996, 34:63-69.
40. Roilides E, Holmes A, Blake C, et al.: Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis 1994, 170:894-899. (Pubitemid 24296569)
41. Bandera A, Trabattoni D, Ferrario G, et al.: Interferon-gamma and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis. Infection 2008, 36:368-373.
42. Safdar A, Rodriguez G, Rolston KV, et al.: High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 39:157-164. (Pubitemid 46178750)
43. Bodey GP, Anaissie E, Gutterman J, et al.: Role of granulocytemacrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993, 17:705-707. (Pubitemid 23293383)
44. Emminger W, Emminger-Schmidmeier W, Peters C, et al.: Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rhGM-CSF) treatment of a patient in a continuous febrile state. Blut 1990, 61:219-221.
45. Rodriguez G, Georgescu G, Islam S, Safdar A: Safety of granulocyte macrophage-colony stimulating factor (GM-CSF) in 66 cancer patients with invasive fungal infections [abstract #3520]. Paper presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting. Washington, DC; October 25-28, 2008.
46. Safdar A, Georgescu G, Rodriguez G, Champlin R: Granulocyte macrophage colony stimulating factor (GM-CSF) in stem cell transplant recipients: response to immune enhancement in early versus late serious post-transplant infections [abstract #2203]. The 2008 Annual Meeting of the American Society of Hematology. Blood (ASH Annual Meeting Abstracts) 2008, 112:4373.
47. Stevens DA: Th1/Th2 in aspergillosis. Med Mycol 2006, 44: S229-S235.
48. Stevens DA, Brummer E, Clemons KV: Interferon-gamma as an antifungal. J Infect Dis 2006, 194:S33-S37.
49. Clemons KV, Kamberi P, Chiller TM, et al.: Effects of interferon-gamma gene therapy in the murine central nervous system and concentrations in cerebrospinal fluid after intrathecal or intracerebral administration. Biotechnology 2005, 4:11-18. (Pubitemid 41038316)
50. Nagai H, Guo J, Choi H, Kurup V: Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995, 172:1554-1560. (Pubitemid 3023470)
51. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl JMed 1991, 324:509-516.
52. Dignani MC, Rex JH, Chan KW, et al.: Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 2005, 104:199-204. (Pubitemid 40847769)
53. Safdar A, Rodriguez G, Ohmagari N, et al.: The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005, 103:731-739. IFN-γ was considered to play a role in GVHD following allogeneic transplantation. This was the first report showing safety of recombinant IFN-γ therapy in allogeneic HSCT recipients; in fact, a number of patients with severe GVHD had improvement in GVHD despite partial withdrawal of anti-GVHD therapy during and immediately after IFN-γ therapy.
54. Steele C, Rapaka RR, Metz A, et al.: The beta-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus. PLoS Pathog 2005, 1:e42.
55. Bellocchio S, Gaziano R, Bozza S, et al.: Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005, 55:214-222. (Pubitemid 40331148)
56. Lewis RE, Chamilos G, Prince RA, et al.: Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 2007, 51:1078-1081. (Pubitemid 46355298)
57. Wheeler RT, Fink GR: A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006, 2:e35.
58. Lamaris GA, Lewis RE, Chamilos G, et al.: Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008, 198:186-192. (Pubitemid 352019283)
59. Hohl TM, Feldmesser M, Perlin DS, et al.: Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis 2008, 198:176-185. (Pubitemid 352019282)
60. Safdar A: Fungal cytoskeleton dysfunction or immune activation triggered by beta-glucan synthase inhibitors: potential mechanisms for the prolonged antifungal activity of echinocandins. Cancer 2009, 115:2812-2815.
61. Safdar A, Rodriguez GH, Lichtiger B, et al.: Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006, 106:2664-2671.
62. Seidel MG, Peters C, Wacker A, et al.: Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008, 42:679-684.